vMap
FDA-cleared AI-based arrhythmia mapping solution from standard ECG
Software · Cloud SaaSCompany source
Company profile
About Vektor Medical
Vektor Medical is advancing care for arrhythmia patients by unlocking insights contained in standard ECG data through artificial intelligence. The company's flagship product, vMap, is an FDA-cleared and CE-marked arrhythmia analysis tool that provides rich 4-chamber cardiac insights from non-invasive ECG mapping. vMap addresses a global health crisis where cardiac arrhythmias cause 10% of global deaths and over 25% of adults over 40 develop serious arrhythmias. The platform is indicated for seven arrhythmias and two pacing types, including atrial and ventricular tachycardia, fibrillation, pacing, premature complexes (PACs and PVCs), and orthodromic atrioventricular reentrant tachycardia. Clinical studies have demonstrated that vMap use is associated with significant reductions in procedure time, improved arrhythmia-free survival rates, and better outcomes in unstable ventricular tachycardia cases. The technology uses forward-solution computational ECG mapping to accurately identify arrhythmia and pacing locations, providing clinically actionable spatial accuracy that supports catheter-based and noninvasive arrhythmia therapies. Vektor Medical serves electrophysiologists and cardiac care teams in health systems, helping them streamline workflows and reduce procedural burden without compromising clinical outcomes.
Company description Vektor Medical official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Vektor Medical?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Atrial fibrillation
- Atrial flutter
- Atrial tachycardia
- Cardiac pacing
- Focal atrial tachycardia
- Orthodromic atrioventricular reentrant tachycardia
- Premature atrial complexes (PACs)
- Premature ventricular complexes (PVCs)
- Unstable VT
- Ventricular fibrillation
- Ventricular tachycardia
Who it serves
- Electrophysiology Labs
- Health Systems
- Hospitals
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEuropean Union · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA clearance and CE mark approval for vMap. Multiple peer-reviewed clinical studies published demonstrating procedural efficiency improvements and clinical outcomes. Expanded indications to cover 7 arrhythmias and 2 pacing types.
Partnerships
Recorded partners
- University of California San Diego
- VA San Diego Healthcare System
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Forward-Solution Noninvasive Computational Arrhythmia Mapping: The VMAP Study.Circulation. Arrhythmia and electrophysiology · Sep 1, 2022
Computational ECG mapping and respiratory gating to optimize stereotactic ablative radiotherapy workflow for refractory ventricular tachycardia.Heart rhythm O2 · Oct 1, 2021
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
86.5% freedom from AF and AT
At 6-month follow-up for PVI + driver ablation vs 48.0% for PVI-only controls
Reduction in procedure time
Time to first ablation and total procedure duration
Reduction in fluoroscopy use
During EP procedures
Reduction in combined endpoint
Death, ICD shocks, and ATP therapies in unstable VT cases
Multi-center VT Study
Ablation for hemodynamically unstable ventricular tachycardia
80% one-year arrhythmia-free survival (free from VT recurrence or death) compared with 43% using conventional strategies
VITAL-EP Registry (Interim)
Real-world AF ablation across paroxysmal, persistent, and longstanding persistent AF
Highly efficient procedures with median fluoroscopy time of 0 minutes, frequent arrhythmia termination, and high rates of post-ablation non-inducibility
Multi-center AF Study
PVI + AF driver ablation for persistent AF, recurrent AF after prior ablation, or AF associated with atrial flutter or focal atrial tachycardia
86.5% freedom from AF and AT at 6-month follow-up versus 48.0% for controls (P = 0.006)
Multi-center Time Study
Improving procedural efficiency by reducing time to ablation, total procedure duration, and fluoroscopy use
Reduction in procedure time and fluoroscopy use compared to traditional methods across 28 vMap cases
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Rob Krummen
CEO
Kelly Perez
CFO & Senior VP of Operations
Chris Villongco
CTO, Inventor, and Co-Founder
Michael Andersen
VP, Sales
Jennifer Bayon
VP, Strategic Growth & Business Development
Chris Schulte
VP, Product Development
Emily Lovell
VP, Marketing
Maurice Pirio
VP, Intellectual Property
06 · Company updates
Updates from Vektor Medical
Recent articles published on Vektor Medical's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.